Skip to main content
. 2018 Nov 6;18:1067. doi: 10.1186/s12885-018-4900-x

Table 1.

Baseline characteristics of the matched neoadjuvant and adjuvant radiotherapy cohorts

Variable N (%) Survival Number of patients (%) P value
Median (IQR), mo Adjuvant RT (N = 377) Neoadjuvant RT (N = 377) Surgery + Chemotherapy
Only (N = 524)
Age, years 61.03 ± 9.52 61.88 ± 9.86 60.23 ± 9.80 61.72 ± 9.04 0.0645
Sex 0.9669
 Male 719 (56.26) 58 (18, NR) 210 (55.70) 213 (56.50) 296 (56.49)
 Female 559 (43.74) 65 (23, NR) 167 (44.30) 164 (43.50) 228 (43.51)
Race 0.5785
 White 1025 (80.20) 61 (19, NR) 303 (80.37) 309 (81.96) 413 (78.82)
 Black 152 (11.89) 79 (18, NR) 47 (12.47) 43 (11.41) 62 (11.83)
 Other 101 (7.90) 57 (26, NR) 27 (7.16) 25 (6.63) 49 (9.35)
Histology 0.8385
 Adenocarcinoma 514 (40.22) 54 (21, NR) 144 (38.20) 150 (39.79) 220 (41.98)
 Squamous cell 356 (27.86) 69 (19, NR) 109 (28.91) 104 (27.59) 143 (27.29)
 Others 408 (31.92) 79 (19, NR) 124 (32.89) 123 (32.63) 161 (30.73)
Grade 0.0366
 I/ II 389 (30.44) 66 (26, NR) 101 (26.79) 107 (28.38) 181 (34.54)
 III/ IV 738 (57.75) 48 (17, NR) 226 (59.95) 218 (57.82) 294 (56.11)
 Unknown 151 (11.82) 103 (35, NR) 50 (13.26) 52 (13.79) 49 (9.35)
T classification 0.4202
 T1 211 (16.51) 73 (28, NR) 70 (18.57) 55 (14.59) 86 (16.41)
 T2 535 (41.86) 54 (20, NR) 160 (42.44) 148 (39.26) 227 (43.32)
 T3 155 (12.13) 46 (15, NR) 40 (10.61) 54 (14.32) 61 (11.64)
 T4 377 (29.50) 66 (18, NR) 107 (28.38) 120 (31.83) 150 (28.63)
N classification 0.2972
 N0/N1 294 (23.00) 81 (21, NR) 82 (21.75) 80 (21.22) 132 (25.19)
 N2/N3 984 (77.00) 56 (19, NR) 295 (78.25) 297 (78.78) 392 (74.81)
Extent of Resection 0.9712
 Lobectomy or Bilobectomy 1056 (82.63) 64 (21, NR) 311 (82.49) 313 (83.02) 432 (82.44)
 Pneumectomy 222 (17.37) 53 (15, NR) 66 (17.51) 64 (16.98) 92 (17.56)
Treatment regimen
 Neoadjuvant RT 377 (29.50) 67 (20, NR)
 Adjuvant RT 377 (29.50) 61 (17, NR)
 Surgery + Chemotherapy Only 524 (41.00) 61 (22, NR)

NR not reached